Jump to main content
Jump to site search


Dihydropyrimidine-2-thiones as Eg5 inhibitors and L-type calcium channel blockers: potential antitumour dual agents

Author affiliations

Abstract

The use of multitarget drugs has evolved as an alternative to “magic bullets” for the treatment of complex diseases such as cancer, in order to affect simultaneously several targets relevant to the disease. We have designed and synthesized a series of dual agents as both Eg5 inhibitors and calcium channel blockers, bearing a 4-aryldihydropyrimidine core. Compound 2 (aryl: 3-nitrophenyl) was selected as potential dual agent due to displaying both activities: it is a vasorelaxant agent (>90% relaxation at 10−5 M in KCl-precontracted aorta rings), it decreases the response to calcium and it is cytotoxic to MCF-7 (breast), HCT-116 (colon) and A-549 (lung) cancer cell lines. The dual mechanism of action was confirmed by blocking (−)-BAY K8644-induced vascular contraction and production of monopolar spindles, typical of Eg5 inhibition. Docking suggests that both (R) and (S)-enantiomers could bind Eg5.

Graphical abstract: Dihydropyrimidine-2-thiones as Eg5 inhibitors and L-type calcium channel blockers: potential antitumour dual agents

Back to tab navigation

Supplementary files

Publication details

The article was received on 22 Feb 2019, accepted on 29 Jun 2019 and first published on 04 Jul 2019


Article type: Research Article
DOI: 10.1039/C9MD00108E
Med. Chem. Commun., 2019, Advance Article

  •   Request permissions

    Dihydropyrimidine-2-thiones as Eg5 inhibitors and L-type calcium channel blockers: potential antitumour dual agents

    E. González-Hernández, R. Aparicio, M. Garayoa, M. J. Montero, M. Á. Sevilla and C. Pérez-Melero, Med. Chem. Commun., 2019, Advance Article , DOI: 10.1039/C9MD00108E

Search articles by author

Spotlight

Advertisements